taurine has been researched along with Depression in 27 studies
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
" Acamprosate, although not approved in the United States, is used in alcoholism treatment in many other parts of the world." | 10.19 | Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. ( Kranzler, HR; Van Kirk, J, 2001) |
"Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 9.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
"This study was conducted to investigate the correlation between dietary taurine intake, nutrients intake, dietary attitudes, dietary behaviors, and life stress by depression in Korean female college students." | 7.91 | Relationship Among Dietary Taurine Intake, Dietary Attitudes, Dietary Behaviors, and Life Stress by Depression in Korean Female College Students. ( Chang, KJ; Kim, SH; Oh, EY; Park, SH, 2019) |
"The purpose of this study was to investigate the dietary taurine intake, nutrients intake, dietary habits and life stress by depression in Korean female college students." | 7.76 | Dietary taurine intake, nutrients intake, dietary habits and life stress by depression in Korean female college students: a case-control study. ( Chang, KJ; Park, JY; You, JS, 2010) |
" Acamprosate, although not approved in the United States, is used in alcoholism treatment in many other parts of the world." | 6.19 | Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. ( Kranzler, HR; Van Kirk, J, 2001) |
"Taurine is an important amino acid required for brain development." | 5.91 | Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss. ( Cai, G; Fan, Z; Han, J; Li, X; Li, Y; Luo, D; Wang, R; Wu, S; Zhang, H; Zhang, L; Zhu, Y; Zhuo, L, 2023) |
"Taurine has been known to be related to certain modifications of the immune system." | 5.32 | Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003) |
"Data were collected during an 8-week randomized controlled trial of acamprosate for individuals with co-occurring bipolar disorder and alcohol dependence (n = 30)." | 5.16 | Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. ( Brady, KT; Brown, DG; Chiuzan, C; DeSantis, SM; Prisciandaro, JJ; Tolliver, BK, 2012) |
"The efficacy of pharmacological relapse prevention in alcoholism with acamprosate and naltrexone has been supported by several controlled trials." | 5.11 | Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. ( Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K, 2005) |
"We investigated the antidepressant effect of creatine (CRE) and taurine (TAU) mixtures on behavioural changes and biomarkers in stress-induced depression in Drosophila melanogaster and a mouse model." | 3.96 | Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways. ( Hong, KB; Jo, K; Kim, S; Suh, HJ, 2020) |
"The combination of acamprosate and escitalopram suppressed EtOH intake in both nonstressed and stressed mice; hence, this combination is potentially helpful for AUD individuals with or without comorbid depression to reduce alcohol use." | 3.83 | Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. ( Aguiar, FS; Choi, DS; Hinton, DJ; Ho, AM; Jia, YF; Karpyak, VM; Qiu, Y; Weinshilboum, RM, 2016) |
"Responder rates for the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Mini-Mental State Examination (MMSE) were measured as improvement or absence of decline from baseline." | 2.72 | Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. ( Ben-Menachem, E; Blennow, K; C-son Silander, H; Ejnell, H; Jonsson, MA; Karlsson, M; Merrill, CA; Minthon, L; Nordlund, A; Rolstad, S; Sjögren, MJ; Warkentin, S, 2006) |
" This review details the adverse effects of IUGR on fetal brain development and discusses intervention strategies." | 2.53 | Neurodevelopment in children with intrauterine growth restriction: adverse effects and interventions. ( Fu, W; Liu, J; Wang, Y, 2016) |
"Taurine is an important amino acid required for brain development." | 1.91 | Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss. ( Cai, G; Fan, Z; Han, J; Li, X; Li, Y; Luo, D; Wang, R; Wu, S; Zhang, H; Zhang, L; Zhu, Y; Zhuo, L, 2023) |
"Taurine was found to inhibit the decrease of sucrose consumption and prevent the deficiency of spatial memory and anxiety in rats exposed to CUMS, suggesting a preventive effect of taurine on depression-like behavior." | 1.46 | Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats. ( Feng, Y; Hu, JM; Lin, SM; Ren, S; Tang, RY; Wu, GF; Xu, C; Yang, JC; Yang, QH; Zhou, JQ, 2017) |
"A well-validated animal model of treatment resistant depression (congenital learned helpless rats = cLH) was investigated by hippocampal in vivo ¹H MRS with and without a 1-week course of electroconvulsive shocks (ECS), an animal model of ECT, and compared to wild type (WT) animals, while saline and clomipramine injections served as additional controls." | 1.38 | Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression. ( Biedermann, S; Ende, G; Gass, P; Hoyer, C; Sartorius, A; Vollmayr, B; Weber-Fahr, W; Zheng, L, 2012) |
"Taurine has been shown to be elevated in plasma and lymphocytes of depressed patients, but the level normalises after successful drug therapy." | 1.38 | Taurine and glutathione levels in plasma before and after ECT treatment. ( Gerdin, G; Ollinger, K; Samuelsson, M; Vrethem, M, 2012) |
"Comorbidity of alcohol abuse and dependence with bipolar disorders is high." | 1.38 | Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.). ( Preuss, UW, 2012) |
"Taurine has been known to be related to certain modifications of the immune system." | 1.32 | Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. ( Baccichet, E; Carreira, I; Lima, L; Obregón, F; Peña, S; Urbina, M, 2003) |
"Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (14.81) | 18.7374 |
1990's | 1 (3.70) | 18.2507 |
2000's | 5 (18.52) | 29.6817 |
2010's | 14 (51.85) | 24.3611 |
2020's | 3 (11.11) | 2.80 |
Authors | Studies |
---|---|
Zhu, Y | 1 |
Wang, R | 1 |
Fan, Z | 1 |
Luo, D | 1 |
Cai, G | 1 |
Li, X | 1 |
Han, J | 1 |
Zhuo, L | 1 |
Zhang, L | 1 |
Zhang, H | 1 |
Li, Y | 1 |
Wu, S | 1 |
Park, SH | 1 |
Oh, EY | 1 |
Kim, SH | 1 |
Chang, KJ | 2 |
Jangra, A | 1 |
Rajput, P | 1 |
Dwivedi, DK | 1 |
Lahkar, M | 1 |
Kim, S | 2 |
Hong, KB | 1 |
Suh, HJ | 1 |
Jo, K | 1 |
Wu, GF | 1 |
Ren, S | 1 |
Tang, RY | 1 |
Xu, C | 1 |
Zhou, JQ | 1 |
Lin, SM | 1 |
Feng, Y | 1 |
Yang, QH | 1 |
Hu, JM | 1 |
Yang, JC | 1 |
de Dios, I | 1 |
Rialp, G | 1 |
Franco, S | 1 |
Romero, M | 1 |
Ortega, M | 1 |
Nieto, Y | 1 |
Sekar, S | 1 |
Grandjean, J | 1 |
Garnell, JF | 1 |
Willems, R | 1 |
Duytschaever, H | 1 |
Seramani, S | 1 |
Su, H | 1 |
Ver Donck, L | 1 |
Bhakoo, KK | 1 |
Wang, Y | 1 |
Fu, W | 1 |
Liu, J | 1 |
Ho, AM | 1 |
Qiu, Y | 1 |
Jia, YF | 1 |
Aguiar, FS | 1 |
Hinton, DJ | 1 |
Karpyak, VM | 1 |
Weinshilboum, RM | 1 |
Choi, DS | 1 |
Park, JY | 1 |
You, JS | 1 |
Biedermann, S | 1 |
Weber-Fahr, W | 1 |
Zheng, L | 1 |
Hoyer, C | 1 |
Vollmayr, B | 1 |
Gass, P | 1 |
Ende, G | 1 |
Sartorius, A | 1 |
Prisciandaro, JJ | 1 |
DeSantis, SM | 1 |
Chiuzan, C | 1 |
Brown, DG | 1 |
Brady, KT | 1 |
Tolliver, BK | 1 |
Caletti, G | 1 |
Olguins, DB | 1 |
Pedrollo, EF | 1 |
Barros, HM | 1 |
Gomez, R | 1 |
Samuelsson, M | 1 |
Gerdin, G | 1 |
Ollinger, K | 1 |
Vrethem, M | 1 |
Iio, W | 1 |
Matsukawa, N | 1 |
Tsukahara, T | 1 |
Toyoda, A | 1 |
Preuss, UW | 1 |
Pałucha-Poniewiera, A | 1 |
Pilc, A | 1 |
Lima, L | 1 |
Obregón, F | 1 |
Urbina, M | 1 |
Carreira, I | 1 |
Baccichet, E | 1 |
Peña, S | 1 |
Kiefer, F | 1 |
Helwig, H | 1 |
Tarnaske, T | 1 |
Otte, C | 1 |
Jahn, H | 1 |
Wiedemann, K | 1 |
Merrill, CA | 1 |
Jonsson, MA | 1 |
Minthon, L | 1 |
Ejnell, H | 1 |
C-son Silander, H | 1 |
Blennow, K | 1 |
Karlsson, M | 1 |
Nordlund, A | 1 |
Rolstad, S | 1 |
Warkentin, S | 1 |
Ben-Menachem, E | 1 |
Sjögren, MJ | 1 |
Soyka, M | 1 |
Roesner, S | 1 |
Swift, RM | 1 |
Kranzler, HR | 1 |
Van Kirk, J | 1 |
Purdy, A | 1 |
Hahn, A | 1 |
Barnett, HJ | 1 |
Bratty, P | 1 |
Ahmad, D | 1 |
Lloyd, KG | 1 |
McGeer, EG | 1 |
Perry, TL | 2 |
Tachiki, KH | 1 |
Hendrie, HC | 1 |
Kellams, J | 1 |
Aprison, MH | 1 |
Bratty, PJ | 1 |
Hansen, S | 1 |
Kennedy, J | 1 |
Urquhart, N | 1 |
Dolman, CL | 1 |
Avery, MD | 1 |
Lupien, PJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial[NCT04874012] | Phase 2 | 94 participants (Anticipated) | Interventional | 2021-06-12 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
Intervention | mmol/kg (Mean) |
---|---|
N-Acetylcysteine | 3.90 |
Gabapentin | 3.93 |
Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
Intervention | mmol/kg (Mean) |
---|---|
N-Acetylcysteine | 21.59 |
Gabapentin | 21.69 |
Placebo Oral Tablet | 22.25 |
4 reviews available for taurine and Depression
Article | Year |
---|---|
Neurodevelopment in children with intrauterine growth restriction: adverse effects and interventions.
Topics: Adult; Antioxidants; Brain; Cerebral Palsy; Child; Cognition Disorders; Depression; Developmental Di | 2016 |
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Ani | 2006 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfi | 1997 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; | 2001 |
4 trials available for taurine and Depression
Article | Year |
---|---|
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior, Ad | 2012 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; | 2005 |
Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibi | 2006 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; | 2001 |
20 other studies available for taurine and Depression
Article | Year |
---|---|
Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss.
Topics: Amino Acids; Animals; Dendritic Spines; Depression; Depressive Disorder, Major; Mice; Mice, Inbred C | 2023 |
Relationship Among Dietary Taurine Intake, Dietary Attitudes, Dietary Behaviors, and Life Stress by Depression in Korean Female College Students.
Topics: Attitude; Case-Control Studies; Cross-Sectional Studies; Depression; Diet; Female; Humans; Republic | 2019 |
Amelioration of Repeated Restraint Stress-Induced Behavioral Deficits and Hippocampal Anomalies with Taurine Treatment in Mice.
Topics: Acetylcholinesterase; Animals; Anxiety; Behavior, Animal; Depression; Hippocampus; Interleukin-1beta | 2020 |
Creatine and taurine mixtures alleviate depressive-like behaviour in Drosophila melanogaster and mice via regulating Akt and ERK/BDNF pathways.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Catecholamines; | 2020 |
Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Dopamine; Fibroblast Growth Fact | 2017 |
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication.
Topics: Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Citalopram; Depression; Dietary S | 2019 |
Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy.
Topics: Anhedonia; Animals; Choline; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; | 2019 |
Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.
Topics: Acamprosate; Alcohol Drinking; Animals; Anxiety; Citalopram; Depression; Drug Therapy, Combination; | 2016 |
Dietary taurine intake, nutrients intake, dietary habits and life stress by depression in Korean female college students: a case-control study.
Topics: Asian People; Body Composition; Body Mass Index; Case-Control Studies; Depression; Diet; Energy Inta | 2010 |
Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression.
Topics: Animals; Choline; Depression; Disease Models, Animal; Electroconvulsive Therapy; gamma-Aminobutyric | 2012 |
Antidepressant effect of taurine in diabetic rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Depression; Diabetes Mellitus, Experi | 2012 |
Taurine and glutathione levels in plasma before and after ECT treatment.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Depression; Electroconvulsive Therapy; Female; Gl | 2012 |
The effects of oral taurine administration on behavior and hippocampal signal transduction in rats.
Topics: Administration, Oral; Animals; Antidepressive Agents; Behavior, Animal; Calcium-Calmodulin-Dependent | 2012 |
Commentary on the study: impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.).
Topics: Alcohol Drinking; Alcoholism; Behavior, Addictive; Bipolar Disorder; Depression; Female; Humans; Mal | 2012 |
Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test.
Topics: Acamprosate; Animals; Antidepressive Agents; Benzamides; Depression; Disease Models, Animal; Dose-Re | 2012 |
Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine.
Topics: Adolescent; Adult; Depression; Female; Humans; Lymphocytes; Male; Mianserin; Middle Aged; Mirtazapin | 2003 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
A rapid column chromatographic procedure for the routine measurement of taurine in plasma of normals and depressed patients.
Topics: Adult; Animals; Autoanalysis; Chromatography, Ion Exchange; Depression; Humans; Rabbits; Reference V | 1977 |
Hereditary mental depression and Parkinsonism with taurine deficiency.
Topics: Age Factors; Aged; Antidepressive Agents; Body Weight; Brain; Depression; Electroconvulsive Therapy; | 1975 |
Cholesterol metabolism and vitamin B6. II. Intestinal cholesterogenesis in vitamin B6 deficient rats.
Topics: Acetates; Animals; Bile Acids and Salts; Carbon Dioxide; Carbon Isotopes; Cholesterol; Depression; H | 1970 |